Infliximab (Remicade) and increased incidence of development of basal cell carcinoma.
J Drugs Dermatol
; 11(5): 655-6, 2012 May.
Article
in En
| MEDLINE
| ID: mdl-22527438
ABSTRACT
Immunosuppression is a known risk factor for the development of non-melanoma skin cancers (NMSC). Certain medications that induce immunosuppression, such as tumor necrosis factor-α (TNF-α) inhibitors, are being used more frequently. We report a case of a young, pregnant woman who was treated with infliximab for Crohn's disease, and subsequently experienced a rapid growth of two pre-existing basal cell carcinomas. As use of TNF-α inhibitors increases, it is important to closely monitor patients for the development of NMSC.
Search on Google
Collection:
01-internacional
Database:
MEDLINE
Main subject:
Skin Neoplasms
/
Carcinoma, Basal Cell
/
Antibodies, Monoclonal
Type of study:
Incidence_studies
/
Risk_factors_studies
Limits:
Adult
/
Female
/
Humans
/
Pregnancy
Language:
En
Journal:
J Drugs Dermatol
Journal subject:
DERMATOLOGIA
Year:
2012
Document type:
Article
Affiliation country:
United States